No Data
No Data
Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
Express News | Creative Medical Technology Holdings: Sees Sufficient Funds to Meet Operating Costs, Capital Expenditure Requirements Through at Least Q2 2025
Roth MKM Maintains Creative Medical Technology(CELZ.US) With Buy Rating, Maintains Target Price $30
Roth MKM analyst Jonathan Aschoff maintains $Creative Medical Technology(CELZ.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate o
Express News | Creative Medical Technology Generated Human Induced Pluripotent Stem Cells IPSC-derived Islet Cells That Produce Human Insulin
Express News | Creative Medical: Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin
Creative Medical Technology Holdings Announces Evolutionary Development of Its IPSCelz Program With the Successful Generation of IPSC Derived Islet Cells That Produce Human Insulin
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a
No Data